Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey

被引:36
作者
Faggiano, Pompilio [1 ]
Pirillob, Angela [2 ]
Griffo, Raffaele
Ambrosetti, Marco [3 ]
Pedretti, Roberto [4 ]
Scorcu, Giampaolo [5 ]
Werren, Marika [6 ]
Febo, Oreste [15 ]
Malfatto, Gabriella [7 ]
Favretto, Giuseppe [8 ]
Sarullo, Filippo [9 ]
Antonini-Canterin, Francesco [10 ]
Zobbi, Gianni [11 ]
Temporelli, Pierluigi [12 ]
Catapano, Alberico L. [13 ,14 ]
机构
[1] Cardiol Spedali Civili Brescia, Brescia, Italy
[2] E Bassini Hosp, Ctr Studio Aterosclerosi, Milan, Italy
[3] Clin Le Terrazze, UO Cardiol & Angiol Riabilitat, Cunardo, VA, Italy
[4] Inst Clin Sci Maugeri, Pavia, Italy
[5] SSD Valutaz & Consulenza Cardiol AO Brotzu, Cagliari, Italy
[6] IMFR Gervasutta, UO Cardiol Riabilitat, Udine, Italy
[7] Ist Auxol Italiano, Milan, Italy
[8] Cardiol Riabilitat Alta Specializzaz Motta di Liv, Motta Di Livenza, Italy
[9] Osped Buccheri La Ferla Fatebenefratelli Palermo, Palermo, Italy
[10] Osped Sacile, Pordenone, Italy
[11] Osped S Anna Castelnovo Monti, Ctr Riabilitaz Cardiol, Reggio Emilia, Italy
[12] Ist Clin Sci Maugeri, Veruno, Italy
[13] Dipartimento Sci Farmacol & Biomol, Milan, Italy
[14] IRCCS Multimed Milano, Brescia, Italy
[15] UO Cardiol Riabilitat, Rivolta Dadda, Italy
关键词
Familial hypercholestemlemia; Coronary artery disease; Lower extremities peripheral disease; Prevalence; Statins; EZETIMIBE; SIMVASTATIN; CLINICIAN; DIAGNOSIS; GUIDANCE; PANEL;
D O I
10.1016/j.ijcard.2017.10.105
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: Familial hypercholesterolemia (FH) is a genetic disorder characterized by high levels of low density lipoprotein cholesterol (LDL-C) predisposing to premature cardiovascular disease. Its prevalence varies and has been estimated around 1 in 200-500. The Heredity survey evaluated the prevalence of potential FH and the therapeutic approaches among patients with established coronary artery disease (CAD) or peripheral artery disease (PAD) in which it is less well documented. Methods: Data were collected in patients admitted to programs of rehabilitation and secondary prevention in Italy. Potential FH was estimated using Dutch Lipid Clinic Network (DLCN) criteria. Potential FH was defined as having a total score >= 6. Results: Among the 1438 consecutive patients evaluated, the prevalence of potential 11-1 was 3.7%. The prevalence was inversely related to age, with a putative prevalence of 1:10 in those with <55 yrs of age (male) and <60 yrs (female). Definite FH (DLCN score > 8) had the highest percentages of patients after an ACS (75% vs 52.5% in the whole study population). At discharge, most patients were on high intensity statin therapy, but despite this, potential FH group still had a higher percentage of patients with LDL-C levels not at target and having a distance from the target higher than 50%. Conclusions: Among patients with established coronary heart disease, the prevalence of potential FH is higher than in the general population; the results suggest that a correct identification of potential FH, especially in younger patients, may help to better manage their high cardiovascular risk. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:193 / 198
页数:6
相关论文
共 18 条
[1]   Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGE prevalence review [J].
Austin, MA ;
Hutter, CM ;
Zimmern, RL ;
Humphries, SE .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2004, 160 (05) :407-420
[2]   2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) [J].
Catapano, Alberico L. ;
Graham, Ian ;
De Backer, Guy ;
Wiklund, Olov ;
Chapman, M. John ;
Drexel, Heinz ;
Hoes, Arno W. ;
Jennings, Catriona S. ;
Landmesser, Ulf ;
Pedersen, Terje R. ;
Reiner, Zeljko ;
Riccardi, Gabriele ;
Taskinen, Marja-Riita ;
Tokgozoglu, Lale ;
Verschuren, W. M. Monique ;
Vlachopoulos, Charalambos ;
Wood, David A. ;
Luis Zamorano, Jose .
ATHEROSCLEROSIS, 2016, 253 :281-344
[3]   Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society [J].
Cuchel, Marina ;
Bruckert, Eric ;
Ginsberg, Henry N. ;
Raal, Frederick J. ;
Santos, Raul D. ;
Hegele, Robert A. ;
Kuivenhoven, Jan Albert ;
Nordestgaard, Borge G. ;
Descamps, Olivier S. ;
Steinhagen-Thiessen, Elisabeth ;
Tybjrg-Hansen, Anne ;
Watts, Gerald F. ;
Averna, Maurizio ;
Boileau, Catherine ;
Boren, Jan ;
Catapano, Alberico L. ;
Defesche, Joep C. ;
Hovingh, G. Kees ;
Humphries, Steve E. ;
Kovanen, Petri T. ;
Masana, Luis ;
Pajukanta, Paivi ;
Parhofer, Klaus G. ;
Ray, Kausik K. ;
Stalenhoef, Anton F. H. ;
Stroes, Erik ;
Taskinen, Marja-Riitta ;
Wiegman, Albert ;
Wiklund, Olov ;
Chapman, M. John .
EUROPEAN HEART JOURNAL, 2014, 35 (32) :2146-U100
[4]   Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology [J].
De Backer, Guy ;
Besseling, Joost ;
Chapman, John ;
Hovingh, G. Kees ;
Kastelein, John J. P. ;
Kotseva, Kornelia ;
Ray, Kausik ;
Reiner, Zeljko ;
Wood, David ;
De Bacquer, Dirk .
ATHEROSCLEROSIS, 2015, 241 (01) :169-175
[5]  
Defesche Joep C, 2004, Semin Vasc Med, V4, P59
[6]   Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia [J].
Gagné, C ;
Gaudet, D ;
Bruckert, E .
CIRCULATION, 2002, 105 (21) :2469-2475
[7]   Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales [J].
Haralambos, K. ;
Whatley, S. D. ;
Edwards, R. ;
Gingell, R. ;
Townsend, D. ;
Ashfield-Watt, P. ;
Lansberg, P. ;
Datta, D. B. N. ;
McDowell, I. F. W. .
ATHEROSCLEROSIS, 2015, 240 (01) :190-196
[8]   Familial Hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia [J].
Hopkins, Paul N. ;
Toth, Peter P. ;
Ballantyne, Christie M. ;
Rader, Daniel J. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2011, 5 (03) :S9-S17
[9]   Diagnosis and treatment of familial hypercholesterolaemia [J].
Hovingh, G. Kees ;
Davidson, Michael H. ;
Kastelein, John J. P. ;
O'Connor, Anne M. .
EUROPEAN HEART JOURNAL, 2013, 34 (13) :962-+
[10]   Simvastatin with or without ezetimibe in familial hypercholesterolemia [J].
Kastelein, John J. P. ;
Akdim, Fatima ;
Stroes, Erik S. G. ;
Zwinderman, Aeilko H. ;
Bots, Michiel L. ;
Stalenhoef, Anton F. H. ;
Visseren, Frank L. J. ;
Sijbrands, Eric J. G. ;
Trip, Mieke D. ;
Stein, Evan A. ;
Gaudet, Daniel ;
Duivenvoorden, Raphael ;
Veltri, Enrico P. ;
Marais, A. David ;
de Groot, Eric .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (14) :1431-1443